Health Economics›Prostate cancer›Hormonal therapy for locally advanced or metastatic disease

Hormonal therapy for locally advanced or metastatic disease

Prostate cancer · 4 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cyproterone acetate monotherapy Variant #01	—	R 2 261	7d	—	—	~2	~R 4 522 indirect	—
DES monotherapy Variant #01 Partial	—	—	28d	—	—	~2	—	—
Castration Variant #01 Partial	—	—	—	—	—	~1	—	—
Cortisone monotherapy Variant #01 Partial	—	—	—	—	—	~1	—	—

4 of 4 regimens shown